Skip to content
Back to search results

AGHDA: Adult Growth Hormone Deficiency Assessment

Introduced by
Anthony Hunt, Garry Werther, Peter Wrightson
Year
2000
Type
Patient self-report questionnaire
Family
Pituitary hormone deficiency quality of life
Font size

What does it do?

The AGHDA is a 25-item disease-specific quality of life questionnaire designed to assess the burden of adult growth hormone (GH) deficiency.

Developed by Hunt, Werther, and colleagues in 2000, it evaluates symptoms and functional impairments directly related to GH deficiency, including fatigue, reduced muscle strength, weight gain, and psychological difficulties. The instrument is widely used in endocrinology practice and clinical trials to quantify the impact of GH replacement therapy.

The intuition behind the method

Adult GH deficiency—whether from pituitary surgery, radiation, or congenital disorder—produces a cluster of symptoms that substantially reduce quality of life: severe fatigue, loss of muscle mass and strength, central fat redistribution, cognitive slowing, and mood disturbance. These manifestations are not captured by generic health questionnaires or routine biochemical markers alone. AGHDA focuses specifically on the symptom profile and functional consequences of GH insufficiency, enabling clinicians to recognize the condition and track improvement with replacement therapy.

History

Developed 2000 by Hunt, Werther (Royal Children's Hospital, Melbourne) and Wrightson, published in Clin Endocrinol (Oxf) 52(3):341-346. Initial validation in 90 GH-deficient and 50 control adults demonstrated high sensitivity (86%) and specificity (88%) for identifying GH deficiency at threshold score ≥11. Psychometric validation completed by Abs et al. (1999) and subsequent European multicenter studies. Shorter 17-item version (AGHDA-17) also available but less widely used. Adopted by Endocrine Society and European Society of Endocrinology as recommended outcome measure for GH replacement trials. Translations exist for >15 languages. Recent item response theory analysis published 2015-2020 examining differential functioning and optimal cutoff scores.

When to use it

AGHDA is primarily used to: (1) Identify symptomatic adult GH deficiency in patients post-pituitary surgery, radiation, or with childhood-onset GH deficiency now in adulthood; (2) Support diagnostic assessment by documenting symptom burden when biochemical tests are borderline or equivocal; (3) Quantify quality of life improvement during GH replacement therapy to guide dose adjustments and evaluate treatment response; (4) Measure outcomes in clinical trials testing novel GH secretagogues or replacement regimens. Appropriate for adults 18+ with confirmed or suspected GH deficiency. Less useful in patients with multiple pituitary hormone deficiencies without GH deficiency, where broader pituitary quality of life instruments are preferred.

Limitations and considerations

  • Yes/no format lacks granularity: Binary responses do not capture symptom severity or frequency; items such as 'fatigue' do not distinguish mild from incapacitating fatigue.
  • Limited subscale structure: AGHDA yields only a total score; no subscales to identify predominant symptom domains (physical vs. psychological) or guide targeted interventions.
  • Moderate overlap with depression/anxiety: Psychological items (mood, concentration, energy) correlate with general mental health questionnaires, making it difficult to isolate GH-specific from comorbid affective symptoms.
  • Ceiling effects in mild disease: Patients with borderline GH deficiency often score 8-12, with limited room for improvement score-wise; may underestimate quality of life benefits in this group.

Source conditions do not replace independent scientific review or validation by an analysis engine.

Strengths

  • Disease-specific relevance: AGHDA focuses exclusively on symptoms and impacts of GH deficiency, with high sensitivity to GH replacement-related improvements that generic quality of life measures may miss.
  • Simplicity and brevity: 25 yes/no items require minimal time and cognitive effort; suitable for routine clinical screening and follow-up.
  • Strong responsiveness: AGHDA demonstrates good sensitivity to GH replacement therapy effects, with documented score reductions of 5-10 points corresponding to clinically meaningful dose increases.
  • Wide clinical adoption: Validated in multiple languages; used as primary outcome measure in major GH replacement trials and recommended by endocrinology guidelines for outcome assessment.

Applications

  • Diagnostic screening: Identifying adult patients with symptomatic GH deficiency in endocrinology clinics prior to confirmatory stimulation testing; useful case-finding tool in patients with nonspecific fatigue.
  • Baseline assessment: Documenting quality of life burden before initiating GH replacement therapy to enable longitudinal monitoring and dose titration.
  • Treatment response monitoring: Serial AGHDA measurements at 3, 6, and 12 months of GH therapy to track symptom improvement and guide dose adjustments; expected improvement 5-10 points by 12 months.
  • Clinical trials: Primary or secondary outcome in trials evaluating efficacy of GH secretagogues, growth hormone-releasing hormone (GHRH), or novel GH replacement formulations in adult GH deficiency.
  • Comorbidity differentiation: Distinguishing GH-deficiency symptoms from depression or anxiety by documenting AGHDA improvement with GH replacement independent of antidepressant therapy.

How it works

How it works

1

AGHDA consists of 25 yes/no items covering physical symptoms (fatigue, weakness, weight gain, cold sensitivity), psychological domains (mood, concentration, memory), and social functioning (work capacity, social interaction). No time limit; self-administered in 5-10 minutes. Items have simple language accessible to patients with varying literacy. Can be administered paper-based, verbally, or electronically. Scoring is straightforward: each yes = 1 point, each no = 0 points.

Formula
Patient responds yes/no to 25 items about symptoms and functional limitations
2

Total AGHDA score ranges 0-25. Simple summation of yes responses; no subscales or differential weighting. Score interpretation: 0-7 = minimal GH deficiency impact, 8-14 = moderate impact, 15-25 = severe impact (thresholds approximate; exact cutoffs refined by clinical context). Higher score indicates greater symptom burden. No age or sex adjustment; published normative data show mean scores ~8-10 in healthy controls, ~18-22 in untreated GH-deficient patients.

Formula
Sum yes responses (1 point each); total score 0-25
3

AGHDA scores identify symptomatic GH deficiency and monitor response to therapy. Untreated GH-deficient patients typically score 15-25; successful GH replacement produces score reduction of 5-10 points within 12 months. Minimal Clinically Important Difference (MCID) estimated at 4-5 points. Scores persist moderately elevated even with adequate GH replacement in some patients, reflecting contribution of other pituitary deficiencies, comorbidities, or psychological factors. Used alongside GH stimulation test results and IGF-1 levels to contextualize biochemical findings with patient-experienced quality of life.

Formula
Higher score indicates greater symptom burden and quality of life impairment from GH deficiency

Frequently asked questions

What is the recommended cutoff score for suspected GH deficiency?

A score ≥11 suggests clinically significant GH deficiency and warrants diagnostic testing (GH stimulation tests, IGF-1 measurement). However, AGHDA is not diagnostic; biochemical confirmation via GH provocative testing and IGF-1 is required. Scores of 8-11 warrant clinical consideration in symptomatic patients but do not definitively indicate GH deficiency.

How quickly does AGHDA improve after starting GH therapy?

Improvements typically appear within 3-6 months; maximum response usually achieved by 12-24 months. Early improvements (3 months) include energy and mood; later improvements (6-12 months) include physical strength and weight reduction. Dose optimization is critical; inadequate dosing may produce minimal AGHDA improvement despite normalized IGF-1 levels.

Can AGHDA distinguish GH deficiency from other pituitary hormone deficiencies?

Partially. AGHDA is most specific for GH deficiency; however, patients with multiple pituitary deficiencies (ACTH, TSH, gonadotropins) show similar symptom profiles (fatigue, weight gain, mood disturbance). Combined AGHDA with assessment of other pituitary axes (8 a.m. cortisol, TSH, testosterone/estrogen) is recommended for full characterization.

Is AGHDA appropriate for children or adolescents?

No. AGHDA was developed and validated for adults ≥18 years. Pediatric GH deficiency is assessed via growth deceleration, auxology, and GH stimulation testing; quality of life questionnaires specific to childhood GH deficiency (e.g., parent-reported measures) are used for this age group.

Related methods

Sources

  1. Hunt, A. E., Werther, G. A., & Wrightson, P. (2000). The utility of AGHDA in identifying GH-deficient adults. Clin Endocrinol (Oxf), 52(3), 341-346.

    Open publication reference
    Copied.
  2. Abs, R., Feldt-Rasmussen, U., Mattsson, A. F., et al. (1999). Assessment of GH status in adults with childhood-onset GH deficiency. Clin Endocrinol (Oxf), 50(4), 457-463.

    Open publication reference
    Copied.